Laureate, Tolerx Enter Manufacturing Pact

Laureate Pharma has entered into a cGMP contract manufacturing agreement with Tolerx, Inc. to produce Tolerx’s humanized anti-GITR antibody known as TRX518, which is currently in development for cancer and chronic viral indications. Details of the agreement were not disclosed.
   
“The partnership with Tolerx validates the progress we have made in biomanufacturing and our commitment in helping our clients bring novel therapies to the market,” said Robert J. Broeze, Ph.D., president and chief executive officer of Laureate. “With our well-established monoclonal antibody experience, we will partner closely with the Tolerx team to help them achieve their manufacturing objectives.”
   
“Laureate Pharma has a proven track record in biopharmaceutical manufacturing, including capabilities in both clinical and commercial-grade materials,” said Dr. Douglas J. Ringler, president and chief executive officer of Tolerx. “This agreement enables us to operationally leverage Laureate’s expertise and infrastructure while we seek to establish new treatment paradigms in the immunology space.”